Alcohol consumption poses a significant global health risk, contributing to numerous diseases and injuries, especially among ...

There is no standard of care for fibrolamellar liver cancer, no targeted therapies. But that may be changing, thanks to recent findings by rare cancer researcher Dr. Taran Gujral, head of Fred Hutch's ...

Hepatocellular carcinoma (HCC) is a common malignant tumor and the third leading cause of cancer-related mortality. The lack ...

They have an increased risk of dying from both liver diseases and common diseases such as cancer and cardiovascular ... The actual functions of this cell type have hardly been studied to ...

Replimune Group, Inc.'s RP1 + OPDIVO for advanced melanoma gains FDA Priority Review. PDUFA date: July 22, 2025. Read more on ...

A new study reveals how a critical imbalance in bile acids—the substances made by the liver that help digest fats—can trigger ...

Hepatocellular carcinoma (HCC), the most common form of liver cancer, continues to pose a significant global health challenge ...

Liver cancer poses significant challenges due to its complex causes and resistance to conventional treatments, highlighting the need for innovative ...

A protein identified nearly 40 years ago for its ability to stimulate the production of red blood cells plays a surprising, ...

Two international academic journals have found that it is effective to apply classical treatments to patients with advanced ...

When they are broken down inside our cells they produce pyruvate, but to get the most out of this molecule it needs to be transferred inside the cell's powerhouses, the mitochondria. There ...

But elevated enzymes can lead to liver cancer over time. The once-a-day version of the pill was in early-stage testing as researchers were trying to figure out the best dose for patients.